Fate Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $31.2 million, a decrease from the $37.6 million loss recorded in the same period of 2025. The company's collaboration revenue for the quarter was $1.3 million, down from $1.6 million year-over-year. Total operating expenses decreased to $34.3 million from $42.9 million, primarily due to reductions in research and development costs, which fell to $24.7 million from $29.1 million, and general and administrative expenses, which decreased to $9.6 million from $13.8 million.
The company’s cash and cash equivalents stood at $39.6 million as of March 31, 2026, down from $46.6 million at the end of 2025. Total current assets decreased to $179.5 million from $208.7 million, while total liabilities decreased to $30.7 million from $36.1 million. Fate Therapeutics reported an accumulated deficit of $1.6 billion, reflecting its ongoing investment in research and development without generating revenue from product sales.
Strategically, Fate Therapeutics continues to focus on its proprietary induced pluripotent stem cell (iPSC) technology platform, which is central to its development of off-the-shelf cellular immunotherapies. The company has multiple iPSC-derived product candidates in various stages of clinical and preclinical development. The company has also entered into significant collaboration agreements, including a partnership with Ono Pharmaceutical Co., Ltd., which has been expanded to include additional product candidates and increased funding commitments.
Operationally, the company has made progress in its clinical trials and collaborations, although it faces challenges typical of the biotechnology sector, including regulatory hurdles and the need for substantial funding to support ongoing development. Fate Therapeutics anticipates that its existing cash and investments will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the potential need for additional capital to support its research and development activities, which may be influenced by market conditions and the success of its product candidates in clinical trials.
About FATE THERAPEUTICS INC
Fate Therapeutics is a biopharmaceutical company developing off-the-shelf cellular immunotherapies using proprietary induced pluripotent stem cell (iPSC) technology. Its focus includes engineered T-cell and natural killer (NK) cell products for autoimmune diseases and solid tumors. The company leverages innovative synthetic controls, gene editing, and scalable manufacturing to create targeted, durable, and accessible cell therapies aimed at addressing unmet medical needs across cancer and autoimmune indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.